SCHEMBL4407638

SCHEMBL4407638

CCOc1cc(CC(=O)O)c(F)c(OCC)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.43
RXRA P19793 2/20 0.42
RXRB P28702 2/20 0.42
RXRG P48443 2/20 0.42
KDM4E B2RXH2 2/20 0.42
THRB P10828 1/20 0.40
SQSTM1 Q13501 1/20 0.39
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
GLA P06280 1/20 0.39
TSHR P16473 3/20 0.37
MAPT P10636 2/20 0.37
CAMK2A Q9UQM7 1/20 0.37
ABL1 P00519 1/20 0.37
POLB P06746 1/20 0.37
RECQL P46063 1/20 0.37
RIN1 Q13671 1/20 0.37
CTDSP1 Q9GZU7 1/20 0.37
CYP3A4 P08684 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4404615 0.91 HSD17B10 (0.51) HSD17B10RXRARXRBRXRGKDM4E
SCHEMBL4395632 0.91 HSD17B10 (0.51) HSD17B10RXRARXRBRXRGKDM4E
SCHEMBL4405629 0.84 POLB (0.44) HSD17B10RXRARXRBRXRGKDM4E
SCHEMBL4403037 0.84 MAPT (0.47) HSD17B10RXRARXRBRXRGKDM4E
SCHEMBL5037900 0.82 L3MBTL1 (0.42) HSD17B10RXRARXRBRXRGKDM4E
SCHEMBL4403715 0.80 KDM4E (0.39) KDM4EL3MBTL1TSHRCYP3A4FFAR1
SCHEMBL27616067 0.80 KDM4E (0.39) HSD17B10KDM4EL3MBTL1TSHRMAPT
SCHEMBL4395434 0.78 HSD17B10 (0.61) HSD17B10RXRARXRBRXRGKDM4E
SCHEMBL4395957 0.78 TSHR (0.50) HSD17B10KDM4EL3MBTL1TSHRPOLB
SCHEMBL4403330 0.77 TSHR (0.44) HSD17B10RXRARXRBRXRGKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1549651-B1 PYRIMIDOPYRIMIDONES AS KINASE INHIBITORS WARNER LAMBERT CO (US) 2009-12-23 EP disclosed
US-7196090-B2 Kinase inhibitors WARNER-LAMBERT COMPANY (US) 2007-03-27 US disclosed
EP-1549651-A1 KINASE INHIBITORS Warner-Lambert Company LLC (US) 2005-07-06 EP disclosed
WO-2004011465-A1 KINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-05 WO disclosed
US-20040019210-A1 Kinase inhibitors CHIVIKAS CONNOLLY CLEO J (US) 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019210-A1 Kinase inhibitors CDK2, CDK1, CDK4 HSD17B10 2499/4885RXRA 3990/4885RXRB 3638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.